Literature DB >> 23924358

Toll-like receptor 7 rapidly relaxes human airways.

Matthew G Drake1, Gregory D Scott, Becky J Proskocil, Allison D Fryer, David B Jacoby, Elad H Kaufman.   

Abstract

RATIONALE: Toll-like receptors (TLRs) 7 and 8 detect respiratory virus single-stranded RNA and trigger an innate immune response. We recently described rapid TLR7-mediated bronchodilation in guinea pigs.
OBJECTIVES: To characterize TLR7 expression and TLR7-induced airway relaxation in humans and in eosinophilic airway inflammation in guinea pigs. To evaluate the relaxant effects of other TLRs.
METHODS: Human airway smooth muscle strips were contracted with methacholine in vitro, and responses to TLR7 and TLR8 agonists were assessed. TLR7-mediated nitric oxide production was measured using a fluorescent indicator, and TLR7 expression was characterized using immunofluorescence. TLR7 signaling was also evaluated in ovalbumin-challenged guinea pigs.
MEASUREMENTS AND MAIN RESULTS: The TLR7 agonist imiquimod (R837) caused rapid dose-dependent relaxation of methacholine-contracted human airways in vitro. This was blocked by the TLR7 antagonist IRS661 and by inhibiting nitric oxide production but not by inhibiting prostaglandin production. TLR7 activation markedly increased fluorescence of a nitric oxide detector. TLR7 was expressed on airway nerves, but not airway smooth muscle, implicating airway nerves as the source of TLR7-induced nitric oxide production. TLR7-mediated relaxation persisted in inflamed guinea pigs airways in vivo. The TLR8 agonists polyuridylic acid and polyadenylic acid also relaxed human airways, and this was not blocked by the TLR7 antagonist or by blocking nitric oxide or prostaglandin production. No other TLRs relaxed the airways.
CONCLUSIONS: TLR7 is expressed on airway nerves and mediates relaxation of human and animal airways through nitric oxide production. TLR7-mediated bronchodilation may be a new therapeutic strategy in asthma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23924358      PMCID: PMC3826186          DOI: 10.1164/rccm.201303-0442OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  46 in total

1.  Treatment of allergic airway inflammation and hyperresponsiveness by imiquimod modulating transcription factors T-bet and GATA-3.

Authors:  Tao Bian; Kai-sheng Yin; Shu-xian Jin; Xi-long Zhang; Jin-yong Zhou; Xiu-qin Ma; Jing-jing Hu; Wei De
Journal:  Chin Med J (Engl)       Date:  2006-04-20       Impact factor: 2.628

2.  Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms.

Authors:  Ingel K Demedts; Ken R Bracke; Tania Maes; Guy F Joos; Guy G Brusselle
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-20       Impact factor: 6.914

3.  The functional effects of physical interactions among Toll-like receptors 7, 8, and 9.

Authors:  Jianyong Wang; Yu Shao; Teri A Bennett; Raji A Shankar; Paul D Wightman; Laxma G Reddy
Journal:  J Biol Chem       Date:  2006-10-13       Impact factor: 5.157

4.  Imiquimod attenuates airway inflammation and decreases the expression of thymus and activation regulated chemokine in allergic asthmatic mice.

Authors:  Shu-xian Jin; Kai-sheng Yin; Tao Bian; Pei-li Sun
Journal:  Chin Med J (Engl)       Date:  2006-03-05       Impact factor: 2.628

5.  Respiratory tract viral infections in inner-city asthmatic adults.

Authors:  R L Atmar; E Guy; K K Guntupalli; J L Zimmerman; V D Bandi; B D Baxter; S B Greenberg
Journal:  Arch Intern Med       Date:  1998 Dec 7-21

6.  Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release.

Authors:  Lucia Filì; Simona Ferri; Francesco Guarna; Salvatore Sampognaro; Cinzia Manuelli; Francesco Liotta; Lorenzo Cosmi; Andrea Matucci; Alessandra Vultaggio; Francesco Annunziato; Enrico Maggi; Antonio Guarna; Sergio Romagnani; Paola Parronchi
Journal:  J Allergy Clin Immunol       Date:  2006-08       Impact factor: 10.793

7.  Inhibition of influenza virus replication by nitric oxide.

Authors:  G F Rimmelzwaan; M M Baars; P de Lijster; R A Fouchier; A D Osterhaus
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.

Authors:  Keith K B Gorden; Xiaohong X Qiu; Christine C A Binsfeld; John P Vasilakos; Sefik S Alkan
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

9.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.

Authors:  Franck J Barrat; Thea Meeker; Josh Gregorio; Jean H Chan; Satoshi Uematsu; Shizuo Akira; Bonnie Chang; Omar Duramad; Robert L Coffman
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses.

Authors:  Gavin E Morris; Lisa C Parker; Jon R Ward; Elizabeth C Jones; Moira K B Whyte; Christopher E Brightling; Peter Bradding; Steven K Dower; Ian Sabroe
Journal:  FASEB J       Date:  2006-08-25       Impact factor: 5.191

View more
  16 in total

1.  Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia.

Authors:  Jincheng Yang; Kun Chen; Bin Wang; Liudi Wang; Shuya Qi; Weihua Wang
Journal:  Invest New Drugs       Date:  2019-07-04       Impact factor: 3.850

Review 2.  Update in asthma 2013.

Authors:  Lauren Cohn; Prescott G Woodruff
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

3.  TLR7 agonist-induced bronchodilation: key mechanistic questions remain.

Authors:  Matthew G Drake
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-01       Impact factor: 5.464

4.  TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy.

Authors:  Jian Ye; Yadan Wang; Xia Liu; Lingyun Li; Adeleye Opejin; Eddy C Hsueh; Huanle Luo; Tian Wang; Daniel Hawiger; Guangyong Peng
Journal:  J Immunol       Date:  2017-06-26       Impact factor: 5.422

Review 5.  Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease.

Authors:  Katie M Lebold; David B Jacoby; Matthew G Drake
Journal:  Transfus Med Hemother       Date:  2016-03-22       Impact factor: 3.747

6.  Potential of PEGylated Toll-Like Receptor 7 Ligands for Controlling Inflammation and Functional Changes in Mouse Models of Asthma and Silicosis.

Authors:  Tatiana Paula Teixeira Ferreira; Lívia Lacerda Mariano; Roberta Ghilosso-Bortolini; Ana Carolina Santos de Arantes; Andrey Junior Fernandes; Michelle Berni; Valentina Cecchinato; Mariagrazia Uguccioni; Roberto Maj; Alcide Barberis; Patricia Machado Rodrigues E Silva; Marco Aurélio Martins
Journal:  Front Immunol       Date:  2016-03-11       Impact factor: 7.561

7.  Post-bronchiolitis wheezing is associated with toll-like receptor 9 rs187084 gene polymorphism.

Authors:  Kirsi Nuolivirta; Sari Törmänen; Johanna Teräsjärvi; Juho Vuononvirta; Petri Koponen; Matti Korppi; Merja Helminen; Ville Peltola; Qiushui He
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

8.  Polymorphism in the gene encoding toll-like receptor 10 may be associated with asthma after bronchiolitis.

Authors:  Sari Törmänen; Matti Korppi; Johanna Teräsjärvi; Juho Vuononvirta; Petri Koponen; Merja Helminen; Qiushui He; Kirsi Nuolivirta
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

9.  Badger macrophages fail to produce nitric oxide, a key anti-mycobacterial effector molecule.

Authors:  Kirstin Bilham; Amy C Boyd; Stephen G Preston; Christina D Buesching; Chris Newman; David W Macdonald; Adrian L Smith
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

10.  Microarray Analysis and Detection of MicroRNAs Associated with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Ran Miao; Ying Wang; Jun Wan; Dong Leng; Juanni Gong; Jifeng Li; Yunxia Zhang; Wenyi Pang; Zhenguo Zhai; Yuanhua Yang
Journal:  Biomed Res Int       Date:  2017-08-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.